ELDN
Eledon Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$254.82M
P/E Ratio
—
EPS
$-0.52
Beta
0.84
52W High
$4.60
52W Low
$1.35
50-Day MA
$2.63
200-Day MA
$2.58
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
5.39
PEG Ratio
—
About Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing drugs for patients living with autoimmune diseases and amyotrophic lateral sclerosis (ALS) who require organ or cell transplantation. The company is headquartered in Irvine, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-36.86M |
| Operating Margin | 0.00% |
| Return on Equity | -35.80% |
| Return on Assets | -30.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.81 |
| Price-to-Book | 3.00 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.84 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $75.85M |
| Float | $68.59M |
| % Insiders | 1.14% |
| % Institutions | 61.37% |
Historical Volatility
HV 10-Day
34.10%
HV 20-Day
71.93%
HV 30-Day
66.00%
HV 60-Day
66.38%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($8.00 target)
7
BuyData last updated: 4/16/2026